Company Provides Update on Clinical Trial Design of Upcoming Phase 3 Clinical Trials in Parkinson's Disease on March 20, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, will present an update on...